Marco Albanese recently presented his work in designing novel histidine kinases inhibitors at the CARTNET Symposium in Valencia. He described using Oxford Drug Design proprietary software to optimize fragments targeting the ATP-binding domain of histidine kinases. His work has led to the identification of novel molecules with potential anti-virulence activity.